Logo
Close
Your free order overview

    You currently have not items to display

Logo
Close
Your contact details

Title
Gender
First Name*
Last Name*
Email*
Telephone
Country
Street
Number (+ Bus)
City
Postal code

* required fields


Logo
Close
Order completed!

Thank you

Thank you for choosing Janssen Medical Cloud for ordering your materials.


OPSUMIT® (macitentan) resources

On this page you will find useful information regarding which patients should be initiated on OPSUMIT®, guidance on prescribing and administering OPSUMIT®, access to the 2015 European Society of Cardiology (ESC)/European Respiratory Society (ERS) guidelines and 2018 World Symposium on Pulmonary Hypertension proceedings, and recommendations for screening and diagnosing patients with scleroderma or congenital heart disease (CHD) and suspected pulmonary arterial hypertension (PAH).

Prescribing OPSUMIT®

OPSUMIT® SmPC and patient information leaflet

Access the OPSUMIT® SmPC and patient information leaflet.

PAH guidelines and organisations

2015 ESC/ERS guidelines


2018 WSPH proceedings


Identifying PAH in patients with scleroderma

Scleroderma information guide

Learn how PAH can impact patients with scleroderma.

Scleroderma referral guide

Learn about the investigation and referral pathways for patients with scleroderma and suspected PAH.

Identifying PAH in patients with CHD

CHD information guide

Learn how PAH can impact patients with CHD.

CHD referral guide

Learn about the investigation and referral pathways for patients with CHD and suspected PAH.

Continue reading

Efficacy

Discover how OPSUMIT® can provide a range of benefits for patients with PAH.

Safety and tolerability

OPSUMIT® has a well-characterised and generally manageable safety profile.

Initiation and dosing

OPSUMIT® is recommended in first line as monotherapy and in combination therapy by the 2015 ESC/ERS guidelines.

Request medical information
Contact a Janssen representative
Stay in touch

CHD, congenital heart disease; ERS, European Respiratory Society; ESC, European Society of Cardiology; PAH, pulmonary arterial hypertension; PHA, Pulmonary Hypertension Association; WSPH, World Symposium on Pulmonary Hypertension

CP-220224 ∣ June 2021

OPSUMIT® PRESCRIBING INFORMATION AND ADVERSE EVENT REPORTING